High Frequency Imaging in Patients with Cerebral Amyloid Angiopathy

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Cerebral amyloid angiopathy (CAA), caused by amyloid beta depositions in the walls of small cerebral vessels, is remarkably common in the elderly. Its major clinical consequences include intracerebral hemorrhages (ICH) typically in lobar location, functional dependence (disability) and cognitive impairment. Cortical superficial siderosis (cSS) is a common finding in CAA patients and can even be the only magnetic resonance imaging sign of CAA. cSS is of high prognostic relevance regarding future intracerebral haemorrhage and disability. Previous studies suggest that cSS is caused by recurrent focal subarachnoid hemorrhages (fSAH). However, the exact mechanisms and the temporal dynamics of this highly relevant imaging finding are largely unknown. In addition to hemorrhagic manifestations, such as cSS, CAA patients also show ischemic lesions. Of particular interest are acute ischemic lesions as detected by diffusion imaging, which seem to be highly prevalent. Since haemorrhagic and ischemic lesions require fundamentally different therapeutic strategies, understanding the relevance and interplay of both lesion types is highly important for clinical decision making. The HIFI-CAA cohort study aims to provide novel insights into cSS, acute ischemic lesions and other relevant brain alterations in CAA through high-frequency (monthly) serial magnetic resonance imaging.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• Probable CAA according to the modified Boston criteria with evidence of

‣ cSS or fSAH

⁃ lobar ICH survivors without cSS or fSAH

• Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem)

• Absence of infratentorial siderosis or infratentorial SAH

• MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations

• No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury

• Written informed consent by patient herself/himself prior to study enrolment

Locations
Other Locations
Germany
DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn
RECRUITING
Bonn
DZNE/Magdeburg - Universitätsklinikum Magdeburg
RECRUITING
Magdeburg
Insitute for Stroke and Dementia Research
RECRUITING
Munich
Contact Information
Primary
Martin Dichgans, MD
martin.dichgans@med.uni-muenchen.de
+49 89 4400
Backup
Anna Dewenter, PhD
anna.dewenter@med.uni-muenchen.de
+49 89 4400
Time Frame
Start Date: 2019-03-19
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 75
Treatments
Patients with probable CAA and cSS or fSAH
Patients with probable CAA and cortical superficial siderosis (cSS) or focal subarachnoid haemorrhage (fSAH)
Patients with probable CAA without cSS or fSAH
Patients with probable CAA and intracerebral hemorrhage (ICH; micro- or macrohemorrhage) but without cSS or fSAH
Sponsors
Leads: Martin Dichgans

This content was sourced from clinicaltrials.gov